Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data

References

• National Eye Institute. Diabetic retinopathy data and statistics. 2010. [26 Sept, 2019]. Available from: https://nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/diabetic-retinopathy-data-and-statistics.
   Google Scholar
• U.S. Department of Health and Human Services; National Institutes of Health; National Eye Institute. Diabetic retinopathy: what you should know. 2015. [cited 22 Feb, 2017]. Available from: https://nei.nih.gov/sites/default/files/health-pdfs/Diabetic_Retinopathy_What_You_Should_Know.pdf.
   Google Scholar
• Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26(7):1587–1597.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–1487.
   PubMed Web of Science ®Google Scholar
• Stone TW. Preferences and trends membership survey. Presented at: American Society of Retina Specialists Annual Meeting; August 9–13, 2014. San Diego, CA.
   Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022.
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–1086.e2.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359.
   PubMed Web of Science ®Google Scholar
• Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 2016;134(8):888–896.
   PubMed Web of Science ®Google Scholar
• Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. Ophthalmology. 2007;114(2):238–245.
   PubMed Web of Science ®Google Scholar
• Javitt JC, Zlateva GP, Earnshaw SR, et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008;11(4):563–574.
   PubMed Web of Science ®Google Scholar
• United States Department of Labor Bureau of Labor Statistics. Consumer Price Index. [cited 16 Jan, 2018]. Available from: https://www.bls.gov/cpi/.
   Google Scholar
• Czoski-Murray C, Carlton J, Brazier J, et al. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009;12(5):793–799.
   PubMed Web of Science ®Google Scholar
• Hirneiss C. The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life. Clin Ophthalmol. 2014;8:1703–1709.
   PubMedGoogle Scholar
• Schmier JK, Halpern MT, Covert D, et al. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration. Retina. 2006;26(9):1056–1062.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Labor Bureau of Labor Statistics. The employment situation – September 2016. Table B3. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. [cited 5 Oct, 2016]. Available from: https://www.bls.gov/news.release/archives/empsit_10072016.pdf.
   Google Scholar
• Lipscomb J, Weinstein MC, Torrance GW, et al. Time preference. In: Gold MR, Russell LB, Siegel JE, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p. 214–246.
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375–381.
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables. Natl Vital Stat Rep. 2015;64(11):1–63.
   PubMedGoogle Scholar
• Javitt J, Aiello L, Chiang Y, et al. Preventative eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care. 1994;17(8):909–917.
   PubMed Web of Science ®Google Scholar
• Alva M, Gray A, Mihaylova B, et al. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ. 2014;23(4):487–500.
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Johnson BH, Richhariya A, et al. Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia. Clinicoecon Outcomes Res. 2015;7:337–345.
   PubMed Web of Science ®Google Scholar
• Kushner DS, Peters KM, Johnson-Greene D. Evaluating use of the Siebens Domain Management Model during inpatient rehabilitation to increase functional independence and discharge rate to home in stroke patients. PM R. 2015;7(4):354–364.
   PubMedGoogle Scholar
• Genworth 2016. Annual Cost of Care Study: costs continue to rise, particularly for services in home [news release]. Richmond, VA: Genworth Financial, Inc.; May 10 [cited 16 Jan, 2018]. Available from: http://newsroom.genworth.com/2016-05-10-Genworth-2016-Annual-Cost-of-Care-Study-Costs-Continue-to-Rise-Particularly-for-Services-in-Home.
   Google Scholar
• Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48(2):204–223.
   PubMed Web of Science ®Google Scholar
• Finger RP, Fenwick E, Hirneiss CW, et al. Visual impairment as a function of visual acuity in both eyes and its impact on patient reported preferences. PLoS One. 2013;8(12):e81042.
   PubMed Web of Science ®Google Scholar
• Kiss S, Malangone-Monaco E, Wilson K, et al. Real-world injection frequency and cost of ranibizumab and aflibercept for treatment-naïve diabetic macular edema and patients with neovascular age-related macular degeneration in the United States. Presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23–26, 2018. Boston, MA.
   Google Scholar